Drug Development Database| Pharma R&D| Pharmaprojects

Use the power of over 35 years of data to discover global trends impacting today’s drug development industry.

How it helps
Easily identify opportunities or market saturation with Pharmaprojects. Our expert analysts track new molecular targets entering pipelines, in-and-out licensing activity and conduct primary research on your behalf to uncover additional information around your chosen drug or company. Pharmaprojects links to Trialtrove’s clinical trial intelligence, leveraging the power of both to ensure you stay on top of every clinical trial development for your disease, company, or therapeutic mechanism of interest.

How it works
Pharmaprojects’ intuitive interface supports fast access to drug development results for specific diseases, companies, and countries. These results can appear as graphics-driven analytic dashboards or exportable files.

Quickly tap into Pharmaprojects’ comprehensive data to support your next R&D decision.

Pharmaprojects, Trialtrove

Fixed Dose Combinations in Type 2 Diabetes – Perspectives from the ADA Meeting and Future Development

By Jake Mathon 28 Jun 2017

Pharma companies have repurposed drugs into single pill combinations for years.

Pharmaprojects

Statins Forever Infographic

12 Jun 2017

This informative visual gives you a snapshot view of the current dyslipidemia market and the drugs poised to challenge the unparalleled reign of statins.

Pharmaprojects

R&D Annual Review Webinar

17 May 2017

We will discuss the industry trends by examining the pipeline by company, therapeutic area, disease, target and drug type, using data from Pharma Intelligence’s Phamaprojects.

Pharmaprojects, Sitetrove, Trialtrove

R and D Annual Review Webinar 2017

19 Apr 2017

The R&D Annual Review webinar is happening soon. Take a look back at pharma R&D in 2016 and look ahead to the remainder of the year to get expert insight from the senior experts at Pharma Intelligence during this free webinar.

Pharmaprojects

Cystic Fibrosis Awareness

By Loni Branon 13 Apr 2017

A Look At Prevalence and Current Clinical Trial Activity – Is There More We Could Be Doing?

Pharmaprojects

Pharma R&D Annual Review 2017 Supplement

By Ian Lloyd 13 Apr 2017

Following on from our review of trends in the current pharmaceutical R&D pipeline, published in March 2017, this supplement takes a look at the industry’s success stories of 2016 – the drugs which were launched on to the market for the first time during the year.

Pharmaprojects

Pharma R&D Annual Review 2017

By Ian Lloyd 22 Mar 2017

Thank you for your interest in the latest report from Pharmaprojects, Pharma R&D Annual Review 2017.

Pharmaprojects, Biomedtracker, Trialtrove

Epigenetic Drugs in Oncology: Current Clinical Landscape and Emerging Trends

By Rachel Meighan-Mantha 22 Mar 2017

The field of epigenetics is rapidly expanding and as interest continues to grow, epigenetics has become an increasingly promising area for research.

Pharmaprojects

Statins forever: Is anything set to topple this class’s mighty reign?

22 Mar 2017

With the recent controversy surrounding the approval and launch of the first wave of PCSK9 inhibitors (focussing mainly on the extremely high cost in comparison to statin therapies), it may be easy to forget that the dyslipidaemia space has also been plagued by a number of high profile and costly failures too.

Pharmaprojects

Pharma R&D By Numbers

By Ian Lloyd 22 Mar 2017

Welcome to Pharmaprojects' 2017 review of trends in pharmaceutical R&D.

Pharmaprojects

A Bird’s-Eye View of the Rare Disease Landscape

27 Feb 2017

Over 350 million people worldwide are suffering from rare diseases. Which is why it is necessary to understand the rare disease landscape to date.

Pharmaprojects

Announcing the Clinical and Research Excellence Awards and a call for nominations

By Doro Shin 25 Jan 2016

On April 27, 2016, Informa will host its inaugural Clinical and Research Excellence (CARE) Awards to honor those in clinical R&D who are making a difference and committed to making human lives better.

Pharmaprojects

Upcoming Novel HIV Single Tablet Regimens

By Benjamin Graham 01 Dec 2015

For World AIDS Day, we look at current and upcoming novel single tablet regimens (STRs) for HIV treatment. STR’s primary advantage is that they simplify treatment and this leads to greater patient adherence, lower resistance emergence and overall improved outcomes over more traditional cocktails of antiretroviral drugs

Pharmaprojects

Prostate Cancer Still A Common Occurrence

By Jonathan Stephens 24 Nov 2015

When considering cancer in men, prostate cancer could be described as ‘all too frequent’. Indeed, the annual month of ‘Movember’ is here once again and serves as a stark reminder that men worldwide are still dying too young from this disease.Worldwide prostate cancer is currently the second most common cancer in males and the fourth most common cancer overall, with over 1.1 million new cases diagnosed in 2012

Pharmaprojects

PCSK9 Inhibitors What does the future hold for this controversial new class

By Natasha Boliter 28 Oct 2015

With the recent launch of Regeneron/Sanofi’s Praluent® and Amgen’s Repatha®, which are both fully human anti-PCSK9 monoclonal antibodies, it is interesting to consider the other molecular approaches being pursued in the burgeoning PCSK9 inhibitor arena.

Complete drug development database

What's included

Below are the Feature List

Curated by experts

Drug R&D landscape

Historical trends

Ask-the-Analyst™

Custom tables and charts

Pharma Intelligence: latest

Fixed Dose Combinations in Type 2 Diabetes – Perspectives from the ADA Meeting and Future Development

Statins Forever Infographic

R&D Annual Review Webinar

R and D Annual Review Webinar 2017

Cystic Fibrosis Awareness

Pharma R&D Annual Review 2017 Supplement

Pharma R&D Annual Review 2017

Epigenetic Drugs in Oncology: Current Clinical Landscape and Emerging Trends

Statins forever: Is anything set to topple this class’s mighty reign?

Pharma R&D By Numbers

A Bird’s-Eye View of the Rare Disease Landscape

Announcing the Clinical and Research Excellence Awards and a call for nominations

Upcoming Novel HIV Single Tablet Regimens

Prostate Cancer Still A Common Occurrence

PCSK9 Inhibitors What does the future hold for this controversial new class

Meet the team

Below are the Analyst Profile

Ian Lloyd

Management, Senior Director

Karen Currie

Management, Executive Director, Editorial

Patricia Reilly

Management, Vice President, Intelligence Alliances and Product Unification

Trialtrove: gold standard clinical trials intelligence

Sitetrove: Clinical trial site & investigator identification

Clinical and Research Excellence

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Report store

Pharmaprojects: track pharma R&D

​Complete drug development database

What's included

Below are the Feature List

Curated by experts

Drug R&D landscape

Historical trends

Ask-the-Analyst™

Custom tables and charts

Pharma Intelligence: latest

Meet the team

Below are the Analyst Profile

Ian Lloyd

Management, Senior Director

Karen Currie

Management, Executive Director, Editorial

Patricia Reilly

Management, Vice President, Intelligence Alliances and Product Unification

Related Products

Trialtrove: gold standard clinical trials intelligence

Sitetrove: Clinical trial site & investigator identification

Clinical and Research Excellence

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Report store

Complete drug development database